Navigation Links
Innocoll Announces Closing of $30 Million Equity Financing Investment
Date:12/17/2007

IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In 2005, Innocoll acquired the worldwide marketing rights from Essex Chemis AG, an affiliated company of Schering Plough Corporation (NYSE: SGP) and in August 2007 sold its marketing rights, with the exception of the U.S., to EUSA Pharma. GENTAMICIN SURGICAL IMPLANT is currently in phase 3 clinical development in the U.S. for the prevention of surgical site infections. Innocoll will conduct two US multi- centered phase 3 clinical trials; one in cardiac surgery patients at higher risk of surgical site infection and the other in patients undergoing open colorectal surgery. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the Study Co-ordinating Center for both trials. Independent market research recently performed by L.E.K. Consulting has projected peak U.S. sales of GENTAMICIN SURGICAL IMPLANT at more than $200 million per annum.

Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx GENTAMICIN TOPICAL for the treatment and prevention of infected diabetic foot ulcers and CollaRx BUPIVACAINE IMPLANT for the management of post-operative pain, which are both in Phase 2 clinical trials.

CollaRx GENTAMICIN TOPICAL represents the clinical development of the marketed GENTAMICIN SURGICAL IMPLANT for the topical treatment and prevention of infection in chronic skin ulcers, such as diabetic foot. A high proportion of chronic wounds become clinically infected requiring treatment with antibiotics. Orally administered and injected antibiotics are often associated with systemic side effects and widespread use can lead to develop
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Synthetic Biologics, Inc. (NYSE MKT: SYN), ... of serious infectious diseases, announced today that Jeffrey Riley ... OneMedForum New York Conference on Thursday, June 27, 2013 at ... . Mr. Riley is scheduled to present at 8:40 a.m. ... presentation can be accessed by logging onto the web at ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... plant, stool and other challenging microbial nucleic acid ... Protein Extraction Kit, for extraction of pure protein ... protein world coincides with the 20 th ... growing innovation capabilities. (Photo: http://photos.prnewswire.com/prnh/20130619/LA32633 ...
(Date:6/19/2013)...  Continuing its long history of proven clinical performance ... , Inc. announces the U.S. Food and Drug Administration ... I assay for use on its Access 2 immunoassay ... Beckman Coulter,s troponin I test for over 12 ... performance to continue providing dependability to laboratories supporting emergency ...
(Date:6/19/2013)... , June 19, 2013   NineSigma , ... that a year following its launch, NineSights.com ... a focal point for the worldwide community of innovators. ... climate and environmental sustainability experts, NineSights stands out for ... range of scientific and technical disciplines, all vetted by ...
Breaking Biology Technology:Synthetic Biologics to Present at OneMedForum New York 2013 2MO BIO Laboratories, Inc. launches the first kit for protein extraction from soil 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3
... SAN DIEGO, March 3 Bio-Matrix Scientific Group, ... an emerging research and development biotechnology company focused ... at its commercial cryogenic stem cell bank and ... News/Special Report about trends in adult stem cells ...
... Featured on March 9th ... France , and March 17, 2009, at ... ROCKVILLE, Md., March 3 Sequella, Inc., a clinical-stage ... potential has announced that Alan Klein, Sequella Executive Vice President for ...
... emerging Canadian biotech company focused on developing novel ... of target enrollment in its pilot clinical trial ... hypophosphatasia. Enobia is investigating Enzyme Replacement Therapy ... rare and often crippling genetic bone disorder for ...
Cached Biology Technology:Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016 2Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences 2Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 2Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 3
(Date:6/19/2013)... June 19, 2013 AT&T * ... upcoming launch of the ultimate workhorse among ruggedized ... As one of the most ruggedized phones equipped ... Terrain embodies toughened versatility and business-ready features.  Its ... keep workforces moving forward, while also keeping up ...
(Date:6/19/2013)... MedNet Solutions , a global life ... is pleased to announce its participation in the 2013 ... Boston .  This represents the 10 ... cloud-based eClinical solutions, has exhibited at this premier industry ... iMedNet™ EDC , MedNet,s latest, easy-to-use eClinical technology ...
(Date:6/19/2013)... York, NY, June 19, 2013 A decade-long ... Research in Helmholtz Zentrum Mnchen, Germany, is providing ... and the risk of developing type 1 diabetes ... possible preventions for the disease. The study, "Seroconversion ... to Diabetes in Children," was published today in ...
Breaking Biology News(10 mins):AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 2AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 3AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 4AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 5MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2New data on islet autoantibodies in young children defines early type 1 diabetes development 2
... breast pathology experts will meet between the 20th and 22nd ... International Society (SIS). This meeting and the 29th Congress of ... take place in the Valencia, coinciding with the International Breast ... of the SIS and the SESPM, "this meeting will allow ...
... be treated like any other animal depending on where the ... the Department of Sociology and Anthropology at Indiana University South ... tend to have a city background. "To think of ... areas," Blouin said, "which makes sense given the utilitarian relationships ...
... Love, exercise and, new research shows, an infrared laser can ... Reserve University and Vanderbilt University found that pulsed light can ... damage to the tissue. The work, "Optical pacing of the ... of Nature Photonics on Aug. 15, 2010. ...
Cached Biology News:1,500 worldwide experts debate the latest advances in breast pathologies' treatments in Valencia 2Dogs' family status depends on family's locale 2A heart beats to a different drummer 2
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
... anti-phospho-PTEN (Ser385) ... to amino acid region encompassing ... phospho-PTEN (Ser385), ... Quality Assurance: ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
CCNI Antibody...
Biology Products: